Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

6% had high-grade B-cell lymphoma (double hit or triple hit), 14% had mantle cell lymphoma, 14% had Richter transformation, and 8% had other indolent lymphoma. The median number of previous ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.